Are SIBN insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies SIBN leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Stock Ratings / Health Care / SIBN / insiders

IRMD (55) IART (19) BBNX (36) SGP (43) ⌘ Pro Terminal →

SI-BONE Inc. (SIBN) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$21.23 -5.27% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $20.99

SI-BONE Inc. (SIBN) carries a Roarable Rating of D+ (Sell) with 52/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $951.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SIBN Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SIBN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, SI-BONE Inc. (NASDAQ: SIBN) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 52/100 at a spot price of $21.23 (-5.27% 1D, market cap $951.5M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 16/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, SIBN ranks #244 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SIBN compare to IRMD and IART in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), SIBN carries a Roarable D+ (52/100 RQD), trailing P/E of N/A, gross margin of 79.6%, and ROIC of -10.3%. By comparison, IRMD (iRadimed Corporation) holds a D+ grade (55/100 RQD, P/E 48.8x, ROIC 37.7%, cap $980.5M) and IART (Integra LifeSciences Holdings Corporation) posts a E grade (19/100 RQD, P/E N/A, ROIC -35.0%, cap $992.0M). Among the 5-stock peer group, IRMD leads on earnings multiple (48.8x) while IRMD leads on capital efficiency (37.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SIBN?

▼

Per SIBN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001459839), SI-BONE Inc. generated $200.9M in revenue (+20.2% YoY), -$18.9M in net income, and -$9.1M in free cash flow against $238.6M in total assets and $35.6M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $20.99 (-1.14%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 52/100 (D+) historically posted market-perform odds over rolling 90-day windows (-1.1% avg 90D alpha vs SPY • 50.1% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk C-

Each axis scored 0–20

12M PRICE TARGET CONE-2.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SIBN)Realized 20D OHLCV Swing Band: ±8.1%

Deterministic 5-Pillar Attribution (52/100 Composite)

🔍 WHY SIBN SCORES 52/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+16/20 pts (31% of score)

20D Institutional Volume Accumulation (±8.1% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (27% of score)

Altman Z-Score 8.73 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 6/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$19.68+4.4% Next Q

Q2 (-2Q)

Grade D$20.54+4.4% Next Q

Q3 (-1Q)

Grade D$21.44-1% Next Q

Current

Grade D+$21.23-1.1% Hist 90D α

Trajectory: D (44) → D+ (52)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SIBN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SIBN currently carries a cautious 52/100 (D+) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Big institutional funds and options desks are actively positioning on the bullish side.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($19.50) and Max Pain ($22.29) forces dealer call-delta covering toward $24.38.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SIBN• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “SIBN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 52%NO 48%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

SIBN Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (SIBN)

No recent open-market Form 4 cluster sales or emergency dumps flagged on SIBN. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SIBN)

✓Walkthrough of SIBN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SIBN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +59.03%▲ ASCENDING CHANNEL

2026-11-03O $22.41H $22.41L $21.23C $21.23VOL 1.25M

RES: $23.13SUP: $18.69SMA50: $19.50SMA200: $16.44

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SIBN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SIBN Butterfly Map → + Track SIBN →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. +20.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on SIBN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SIBN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SIBN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SIBN)

Health Care Rank #244 of 1015 ⚔️ IRMD vs SIBN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SIBN vs. IRMD, IART, BBNX, SGP)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, SI-BONE Inc. (SIBN) ranks #244 by composite RQD confidence (52/100, grade D+) and #362 by equity capitalization ($951.5M). Within this direct 5-issuer industry benchmark cohort, IRMD leads on earnings valuation at 48.8x trailing P/E, while IRMD leads on capital efficiency and profitability with 37.7% ROIC and 76.7% gross margin. IRMD currently holds the highest overall quantitative score in the immediate peer group at 55/100 (D+) compared with SIBN at 52/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SIBN ACTIVE SI-BONE Inc.	D+	52/100	—	79.6%	-10.3%	-5.27%	$951.5M	Benchmark Subject
IRMD iRadimed Corporation	D+	55/100	48.8x	76.7%	37.7%	-10.57%	$980.5M	/irmd-vs-sibn →
IART Integra LifeSciences Holdings Corporation	E	19/100	—	50.9%	-35.0%	-0.62%	$992.0M	/iart-vs-sibn →
BBNX Beta Bionics Inc.	D-	36/100	—	55.4%	-22.1%	-4.72%	$910.6M	/bbnx-vs-sibn →
SGP SpyGlass Pharma Inc.	D-	43/100	—	—	-35.0%	-0.83%	$1.08B	/sgp-vs-sibn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001459839 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), SI-BONE Inc. (SIBN) reported GAAP revenue of $200.9M (+20.2% vs. FY2024 revenue of $167.2M , and +44.7% cumulative change since FY2023) , GAAP net income of -$18.9M, operating cash flow of -$675.0K, and free cash flow of -$9.1M (+60.3% YoY). On the balance sheet, SIBN closed FY2025 with $238.6M in total assets against $35.6M in total debt (Altman Z-Score: 8.73, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$200.9M	-$18.9M	-$675.0K	-$9.1M	$238.6M	$35.6M
FY2024 (FY)	2024-12-31	$167.2M	-$30.9M	-$12.4M	-$22.9M	$230.4M	$35.5M
FY2023 (FY)	2023-12-31	$138.9M	-$43.3M	-$18.7M	-$18.7M	—	—

3. SIBN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SIBN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does SIBN compare to IRMD and IART in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for SIBN?

Where is SIBN trading relative to its 50-day, 200-day, and 52-week technical levels?

SIBN last traded at $21.23 (-5.27% on volume of 1,249,200 shares), positioning the stock +8.87% above its 50-day simple moving average ($19.50) and +29.14% above its 200-day simple moving average ($16.44). Across its 52-week range of $11.48 to $22.95, SIBN sits at the 85.0% percentile with a 14-day RSI of 55.4 (BULLISH MOMENTUM) and an implied next-earnings move of ±8.1% ($19.51 to $22.95).

Direct Sub-Reports: SIBN RQD Cockpit SIBN 12M Forecast SIBN Earnings & Move SIBN Dividends & DRIP SIBN Insiders & 13F SIBN Whale Options SIBN Profit Sankey SIBN News & Why

ROARABLE RATING BRIEF • RQD 52/100 (D+) ✓ SEC XBRL & RQD VERIFIED

SIBN — SI-BONE Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

SI-BONE Inc. (SIBN) earns a live Roarable RQD composite score of 52/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $21.23 (-5.27% 1D, market capitalization $951.5M).

Fundamental Cash Engine (9/20): Anchored by return on invested capital (ROIC) of -10.3%, gross margin of 79.6%, operating margin of -11.1%, and free cash flow yield of -0.90%.
Whale 13F & Options Flow (16/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (10/20) + Forensic Balance Sheet (14/20): Incorporates a 1.00x equity beta, Altman Z-Score of 8.73, Piotroski F-Score of 6/9, and Debt/Equity of 0.20x.

2. Business Model, Unit Margins & SEC Financial Trajectory

SI-BONE Inc. Is a NASDAQ-listed issuer in the Health Care sector, Medical/Dental Instruments industry..0B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), SI-BONE Inc. (SIBN) reported $200.9M in annual revenue (up from $167.2M in FY2024, +20.2% YoY) and -$18.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($138.9M revenue, -$43.3M net income) through FY2025, SIBN scaled operating cash flow to -$675.0K and free cash flow to -$9.1M, backed by $238.6M in total assets against $35.6M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (D+ • RQD 52/100): Big institutional funds and options desks are actively positioning on the bullish side. Free cash flow yield of -0.90% and institutional whale pillar of 16/20. With Fundamental Cash Engine at 9/20 and Institutional Whale Flow at 16/20, sustained execution supports upside toward the upper end of the $11.48 – $22.95 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -11.1% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Medical/Dental Instruments (Health Care), SIBN carries a macro regime beta of 1.00 and gross margin of 79.6%.

Key Question #1: Can SIBN sustain or expand its -11.1% operating margin and -10.3% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $200.9M and free cash flow of -$9.1M, how will capital allocation balance growth reinvestment against $35.6M in total debt?
Key Question #3: How sensitive is SIBN's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

SIBN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for SI-BONE Inc. (SIBN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SIBN Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo! Finance Canada • 22h ago

SI-BONE, Inc. (SIBN) Stock Price, News, Quote & History

Yahoo! Finance Canada report covering SI-BONE Inc. (SIBN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE StockInvest.us • 1d ago

Si-bone Stock Price Forecast. Should You Buy SIBN?

StockInvest.us report covering SI-BONE Inc. (SIBN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

SI-BONE (SIBN) Shares Just Moved, So What Is Going On?

Yahoo Finance report covering SI-BONE Inc. (SIBN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Tax withholding requires SI-BONE (SIBN) legal chief to sell 3,133 shares

Stock Titan report covering SI-BONE Inc. (SIBN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com UK • 1d ago

Si-Bone chief op & financial officer sells $94,078 in stock

Investing.com UK report covering SI-BONE Inc. (SIBN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

How Packaging Seal Recall Will Impact SI BONE Stock Investors

Simply Wall St report covering SI-BONE Inc. (SIBN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 1d ago

SI-BONE (SIBN) Edges Higher to $21.83 as Buyers Defend Support - Naked POC

https://www.siam.in/ report covering SI-BONE Inc. (SIBN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

Is SI-BONE (SIBN) Below Fair Value On Its Recall Driven Selloff?

Simply Wall St report covering SI-BONE Inc. (SIBN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SIBN Bull vs. Bear Conversation Board — What's Your Call at $21.23?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SIBN 🐻 33% BEARISH CONVICTION

MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $27.81 (+31.0%)

📌 Pinned Debate

Revenue grew from $138.9M in FY 2023 to $200.9M in FY 2025 with a Debt/Equity of 0.2 and an Altman Z of 8.73, while the whale 13F flow

Don't sleep on SIBN's setup in Health Care. Revenue grew from $138.9M in FY 2023 to $200.9M in FY 2025 with a Debt/Equity of 0.2 and an Altman Z of 8.73, while the whale 13F flow pillar scores 17 of 20.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (52/100) backs up the fundamental quality.

RetailWhale_TX 🐂 BULL

Both sides have a point here — SIBN's 14/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $18.26 (-14.0%)

Spot @ $21.23

ROIC of -10.3%, FCF yield of -0.9%, and an insider conviction pillar score of 3 of 20 indicate the cash engine and insider signals do n

Fading this rally in SIBN at $21.23. ROIC of -10.3%, FCF yield of -0.9%, and an insider conviction pillar score of 3 of 20 indicate the cash engine and insider signals do not yet support the stock's valuation.. With a beta of 1.0 and the stock sitting at $21.23 (52-wk range $11.48–$22.95), the easy multiple expansion is already priced in.